COMPANY
Bedrock Therapeutics
Bedrock Therapeutics has received NIH funding, most recently in fiscal 2025 for the project “Intramuscular Administration of AAV Vectors Encoding soluble PD-L1 for Rheumatoid Arthritis Treatment”. From public records Source · Oct 12, 2026